ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Givosiran (Primary)
- Indications Acute intermittent porphyria; Porphyria
- Focus Registrational; Therapeutic Use
- Acronyms ENVISION
- Sponsors Alnylam Pharmaceuticals
- 07 Nov 2017 Status changed from planning to recruiting, according to an Alnylam Pharmaceuticals media release.
- 07 Nov 2017 According to an Alnylam Pharmaceuticals media release, the company has reached an alignment with the EMA on the design of this trial.
- 07 Sep 2017 According to an Alnylam Pharmaceuticals media release, the company expects interim analysis data in mid-2018.